2197 — Clover Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$3.48bn
- HK$3.05bn
- CNY38.42m
Annual income statement for Clover Biopharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 39.3 | 38.4 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 24.2 | 21.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 910 | 6,008 | 2,446 | 159 | 936 |
| Operating Profit | -910 | -6,008 | -2,446 | -120 | -898 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -913 | -6,016 | -2,452 | -139 | -903 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -913 | -6,016 | -2,452 | -139 | -903 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -913 | -6,016 | -2,452 | -139 | -903 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -913 | -6,016 | -2,452 | -139 | -903 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.787 | -12.9 | -2.19 | -2.11 | -0.753 |